India Sickle Cell Anaemia Market Research Report Information by Type (Sickle Cell Anemia (SS), Sickle Hemoglobin-C Disease (SC), Sickle Beta-Plus Thalassemia, and Sickle Beta-Zero Thalassemia) by Diagnosis & Treatment Type [(Diagnosis (Instruments and Reagents and kits), Treatment, (Pharmacotherapy, (Oral and Parenteral), Blood Transfusion, and Bone Marrow Transplant)] - Forecast till 2032

India Sickle Cell Anaemia Market Overview

India Sickle Cell Anaemia Market size was valued at USD 0.21 billion in 2022. The sickle cell anaemia market industry is projected to grow from USD 0.23 Billion in 2023 to USD 0.90 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 14.68% during the forecast period (2023 - 2032). The growing government support and policies associated with sickle cell Anaemia in India and increased prevalence of sickle cell among India increases the demand for drug treatment are driving market growth.

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

India Sickle Cell Anaemia Market Trends

• The growing government support and policies associated with sickle cell Anaemia in India boosts market growth.

Government support and policies associated with sickle cell anaemia (SCD) in India provide several benefits for individuals affected by the disease including improved access to healthcare, subsidized treatment and medication, and awareness and education programs. Moreover, it also includes inclusion in public health programs and advocacy and policy development. There are several initiatives which Indian government has taken in recent years which bolstered the growth of sickle cell anaemia. For instance. In        July 2023, The National Sickle Cell Anaemia Elimination Mission was launched in Madhya Pradesh and aims to screen approximately 70 million people under 40 years of age in the next three years. The objective of the National Sickle Cell Anaemia Elimination Mission is to eliminate sickle cell anemia by 2047.

Furthermore, overall, government support and policies associated with sickle cell anemia in India play a crucial role in improving healthcare access, reducing financial barriers, raising awareness, and advocating for the needs of affected individuals and their families. These initiatives contribute to better outcomes and quality of life for those living with the disease.

India Sickle Cell Anaemia Market Segment Insights

India Sickle Cell Anaemia Type Insights

The India sickle cell anaemia market segmentation, based on type, includes Sickle Cell Anemia (SS), Sickle Hemoglobin-C Disease (SC), Sickle Beta-Plus Thalassemia, and Sickle Beta-Zero Thalassemia. The sickle cell anemia (SS) segment held the majority share in 2022 in the India sickle cell Anaemia market revenue. This is due to the increasing disease awareness, rise in complications associated with sickle cell anemia, such as hemolysis and vaco-occlusive crisis(voc).

INDIA SICKLE CELL ANAEMIA MARKET SIZE, BY TYPE, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

India Sickle Cell Anaemia Diagnosis & Treatment Type Insights

The India sickle cell anaemia market segmentation is based on product that include diagnosis & treatment type. Furter, the diagnosis segment is further segmented into instruments and reagents and kits. Furthermore, the treatment segment is further bifurcated into pharmacotherapy, blood transfusion, and bone marrow transplant. The pharmacotherapy segment has dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2023-2032. This is attributed to the prevalence of sickle beta-zero thalassemia, a severe form of thalassemia and rising healthcare expenditure.

India Sickle Cell Anaemia Key Market Players & Competitive Insights

The India sickle cell anaemia market is characterized by the presence of many regional, and local vendors. Developments in the healthcare industry and growing research and development make the sickle cell Anaemia market lucrative. To expand their reach and optimize their operational costs, the major players focus on obtaining regulatory authorizations from government agencies for their products and emphasize acquisitions and product launches to gain a substantial market share. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as Cipla Ltd (India), United Biotech Pvt Ltd. (India), Neon (India), and Novartis AG (Switzerland) dominate the India sickle cell anaemia market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.

One of the primary business strategies adopted by manufacturers in the India sickle cell anaemia industry to benefit clients and expand the sickle cell anaemia market sector is to manufacture locally to reduce operating costs.

Cipla Ltd. (Cipla) is a global pharmaceutical company with a portfolio of over 1,000 products across a wide range of therapeutic categories with one quality standard globally. Its products are available in more than 50 dosage forms. The company has 46 manufacturing facilities for the production of APIs and formulations across various therapeutic categories. Its products comply with the Medicines and Healthcare Products Regulatory Agency (MHRA), US FDA, Danish Medicines Agency, Health Canada, Federal Ministry of Health, the National Health Surveillance Agency (ANVISA) Brazil, Medicines Control Council (MCC) South Africa, the Colombia National Food and Drug Surveillance Institute (INVIMA), and Australian Government Department of Health. Cipla has a presence in India, the US, Germany, Norway, Spain, the UK, Sri Lanka, South Africa, Australia, and Brazil.

Also, United Biotech Pvt ltd.  (India)designs, develops, creates, and manufactures cutting-edge products and is actively operating in the pharmaceutical industry. Its product assists in developing manufacturing technologies. It offers product categories including oncology drugs, injectables, tablets, syrups, and ointments. The company products are used in a variety of settings including pharmaceutical and biotechnology laboratories, pilot plants, production facilities, and academic research institutions. It provides its products through more than 21 distributors.

Key Companies in the India Sickle Cell Anaemia Market include

• Cipla Ltd (India)


• United Biotech Pvt Ltd. (India)


• Neon (India)


• Novartis AG (Switzerland)


• Taj Pharmaceuticals Limited. (India)


• Celon Labs (India)


• Salius Pharma Pvt. Ltd (India)


• Pfizer Inc (US)


• Emmaus Medical, Inc (US)


• Teva Pharmaceutical Industries Ltd (Israel)

India Sickle Cell Anaemia Industry Developments

November 2019: The U.S. Food and Drug Administration (FDA) has approved Global Blood Therapeutics as a subsidiary of Pfizer's Oxbryta (Voxelotor), the first medicine specifically targeting the root cause of sickle cell disease. The product is distributed throughout India by the company utilizing an online portal and a network of local distributors.

India Sickle Cell Anaemia Market Segmentation

India Sickle Cell Anaemia Type Outlook

• Sickle Cell Anemia (SS)


• Sickle Hemoglobin-C Disease (SC)


• Sickle Beta-Plus Thalassemia


• Sickle Beta-Zero Thalassemia

India Sickle Cell Anaemia Diagnosis & Treatment Type Outlook

• Diagnosis
  
  
  
  • Instruments
  
  
  • Reagents and kits
  
  
  
  


• Treatment
  
  
  
  • Pharmacotherapy
    
    
    
    • Oral
    
    
    • Parenteral
    
    
    
    
  
  
  
  


• Blood Transfusion


• Bone Marrow Transplant